Paying users zone. Data is hidden behind hidden.

  • Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Bristol-Myers Squibb Co. (BMY)


Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Low level of difficulty

Bristol-Myers Squibb Co., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Short-term debt obligations hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Accounts payable hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Accrued and other current liabilities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Current liabilities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Income taxes payable hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Other non-current liabilities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Long-term debt, excluding current portion hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Non-current liabilities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Total liabilities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Preferred stock hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Common stock hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Capital in excess of par value of stock hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Accumulated other comprehensive loss hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Retained earnings hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Cost of treasury stock hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Total Bristol-Myers Squibb Company shareholders’ equity hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Noncontrolling interest hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Total equity hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Total liabilities and equity hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Bristol-Myers Squibb Co.’s current liabilities as a percentage of total liabilities and equity declined from Q1 2019 to Q2 2019 but then slightly increased from Q2 2019 to Q3 2019.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co.’s non-current liabilities as a percentage of total liabilities and equity increased from Q1 2019 to Q2 2019 but then slightly declined from Q2 2019 to Q3 2019.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Bristol-Myers Squibb Co.’s total liabilities as a percentage of total liabilities and equity increased from Q1 2019 to Q2 2019 but then slightly declined from Q2 2019 to Q3 2019.
Total Bristol-Myers Squibb Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Bristol-Myers Squibb Co.’s total Bristol-Myers Squibb Company shareholders’ equity as a percentage of total liabilities and equity declined from Q1 2019 to Q2 2019 but then slightly increased from Q2 2019 to Q3 2019.